Taking peoplePhase 1
Radioactive DWJ155 Drug Tested in Adults With Advanced Solid Tumors
Tests a radioactive drug in adults with advanced breast, bladder, stomach or lung cancer.
Key facts
- Who runs it
- Novartis Pharma AG
- Where
- Sint-Lambrechts-Woluwe, BelgiumSee the siteAlso in 5 other countries, 10 sites
- Trial code
- Registry title
- A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 64 people, planned
- Started
- 10 Nov 2026
- Expected to end
- 2 Jan 2031
- Type of study
- Interventional
- Record updated
- 21 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with certain advanced solid tumors: breast, bladder, stomach or gastroesophageal junction, and non-small cell lung cancer.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- Advanced breast cancer (HER2+, HR+/HER2-negative or triple-negative), advanced bladder cancer, advanced gastric or gastroesophageal junction adenocarcinoma, advanced non-small cell lung cancer.
Main reasons for not taking part
- Healthy volunteers cannot join.
Where in Belgium
Also in 5 other countries, 10 sites
- Cliniques Universitaires Saint-LucSint-Lambrechts-Woluwe, BelgiumNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Radioactive DWJ155 Drug Tested in Adults With Advanced Solid TumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 21 October 2026